ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 11 for:    TPI | Recruiting, Not yet recruiting, Available Studies

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects (TPI-120)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03206229
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : July 2, 2017
Sponsor:
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
Dr. Apinya Vutikullid, Adello Biologics, LLC

Brief Summary:

This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).

All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: PEG-rhG-CSF Drug: Neulasta (PEG-rhG-CSF) Phase 1

Detailed Description:

The current study design was prepared to assess and compare the PK, PD, safety, tolerability of the Adello biosimilar candidate, TPI-120 and the US-licensed reference product, Neulasta® after administering a single subcutaneous 2 mg dose in healthy adult subjects in a crossover design. The primary PK parameters are AUC0-t, AUC0-inf, and Cmax, and the primary PD parameters are baseline-corrected AUEC0-t and Emax for ANC.

This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).

All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 122 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This study is a Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study
Masking: Double (Participant, Investigator)
Masking Description: This is double blind study so participat healthy subjects and investigators both would be blinded
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study Comparing TPI-120 and Neulasta® Administered Through Subcutaneous Route in Healthy Adult Subjects
Actual Study Start Date : February 13, 2017
Estimated Primary Completion Date : July 20, 2017
Estimated Study Completion Date : September 30, 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: TPI-120 (PEG-rhG-CSF)
PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
Drug: PEG-rhG-CSF
PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Other Name: PEGFILGRASTIM
Active Comparator: Neulasta (PEG-rhG-CSF)
Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
Drug: Neulasta (PEG-rhG-CSF)
PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Other Name: PEGFILGRASTIM



Primary Outcome Measures :
  1. Maximum observed concentration (Cmax) [ Time Frame: 56 days ]
    To evaluate the pharmacokinetics

  2. Area under the concentration-time curve from time zero to the time of the last non-zero concentration (AUC0-t) [ Time Frame: 56 days ]
    To evaluate the pharmacokinetics

  3. Area under the concentration-time curve from time zero to infinity (extrapolated AUC0-inf) [ Time Frame: 56 days ]
    To evaluate the pharmacokinetics


Secondary Outcome Measures :
  1. Safety Variable - Tolerability as measured by Injection Site reactions [ Time Frame: 1, 2, 4, and 24 hours postdose during each study period ]
    Tolerability as measured by Injection Site reactions

  2. Safety Variable - Immunogenicity as measured by presence of Anti Drug Antibodies [ Time Frame: Day 1 of each study period & Day 22 of each study period ]
    Immunogenicity as measured by presence of Anti Drug Antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to dosing), 19 - 55 years of age (inclusive), with body mass index (BMI) ≥ 19 and ≤ 30 kg/m2, and body weight not < 50 kg or > 100 kg at the time of screening.
  2. Healthy as defined by:

    1. The absence of clinically significant (in the opinion of the PI/designee) illness or surgery within 4 weeks prior to dosing.
    2. The absence of a clinically significant (in the opinion of the PI/designee) history of disease.
    3. WBC (white blood cell) > 4.0 x 109/L and < 1.5 times the upper limit of normal (ULN), ANC (absolute neutrophil count) > 2.0 x 109/L and < 1.5 times the upper limit of normal (ULN), Platelet count > 150 x 109/L, AST (aspartate aminotransferase) < 2.5 time the upper limit of normal (ULN), ALT (alanine aminotransferase) < 2.5 time the upper limit of normal (ULN), Serum bilirubin < 1.5 time the upper limit of normal (ULN) and Serum creatinine < 1.5 time the upper limit of normal (ULN). [Refer to APPENDIX 1 for normal reference ranges]
    4. The absence of febrile (defined by a documented oral temperature of 101.5 °F or greater) or infectious illness within 1 week of first dosing.
    5. The absence of a clinically significant history of skin disorders, including psoriasis.
  3. Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study, and for 30 days thereafter.
  4. Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  5. Capable of consent.
  6. Male subjects willing to follow approved birth control method for the duration of the study, and for 30 days thereafter, such as (a double barrier method) vasectomy, condom with spermicide, condom with diaphragm or abstinence, subject should also not donate sperm during this time.

Exclusion Criteria:

  1. Positive test for hepatitis B, hepatitis C, or HIV.
  2. Illicit/illegal drug use as evidenced by a positive test for alcohol or drug screen at screening or check -in.
  3. Positive result for urine alcohol test at screening or check-in
  4. Tobacco use as evidenced by a positive cotinine result at screening or check-in.
  5. History of allergic reactions to pegfilgrastim, filgrastim, Escherichia coli (E. coli)-derived proteins, or other related drugs. History of allergic reactions or hypersensitivity to acetate/acetic acid, polysorbate 20, or sorbitol.
  6. Hereditary fructose intolerance.
  7. Females with positive pregnancy tests at screening or check-in.
  8. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study or completing follow-up activities.
  9. Clinically significant ECG or vital sign abnormalities at screening.
  10. History of significant alcohol abuse within one year prior to initial dosing or regular use of alcohol (more than 14 units of alcohol per week) within six months prior to initial dosing.
  11. History of drug abuse or use of illicit/illegal drugs within 1 year prior to initial dosing.
  12. No medications are permitted during the study. Exceptions are:

    1. Hormonal contraceptives and Hormone Replacement Therapy (HRT),
    2. Thyroid replacement therapy i.e., liothyronine (T3) or levothyroxine (T4).
    3. Acetaminophen
  13. Donation of plasma within 7 days of dosing; blood donation or significant loss of blood within 30 days of dosing.
  14. Participation in a clinical trial involving the administration of an investigational drug or marketed drug within 30 days prior to initial dosing (90 days for biologics) or concomitant participation in an investigational study involving no drug administration.
  15. Females who are breast-feeding or lactating.
  16. History of pulmonary infiltrate or pneumonia (radiologically confirmed) within 6 months prior to initial dosing.
  17. Any past exposure to recombinant human G-CSF products and/or a known history of prior treatment with blood-cell colony stimulating factors, interleukins or interferons.
  18. History of cancer
  19. Subjects who are on a special diet or who have self-reported a weight loss of more than 15 pounds within 1 month prior to initial dosing.
  20. Acute viral or bacterial infection within 1 month prior to initial dosing only if considered clinically significant in the opinion of the Principal Investigator/designee.
  21. History of any clinically significant disease or condition that, in the opinion of the Principal Investigator/designee, would render them unsuitable for inclusion in the study.
  22. Any vaccination (including influenza) within 90 days prior to initial dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03206229


Contacts
Contact: Vaishali C Rawal, MD +1-631-305-8268 vaishali.rawal@adellobio.com
Contact: Prayag N Shah, MD +91-8128671400 dr.prayag@amneal.com

Locations
United States, California
WCCT Global Inc. Recruiting
Cypress, California, United States, 90630
Contact: Henry A Choi, Bachelors degre, Biology    714-252-0700 ext 1168    henry.choi@wcct.com   
Principal Investigator: Apinya Vutikullird, D.O.         
Sponsors and Collaborators
Adello Biologics, LLC
inVentiv Health Clinical

Responsible Party: Dr. Apinya Vutikullid, principal investigator, Adello Biologics, LLC
ClinicalTrials.gov Identifier: NCT03206229     History of Changes
Other Study ID Numbers: TPI-CL-109-A
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Later on management will decide whether to share the data or not

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No